MASAC Issues Safety Information Update on Emicizumab (HEMLIBRA)

The National Hemophilia Foundation’s Medical and Scientific Advisory Council (MASAC) has released a safety information update about Emicizumab (Hemlibra), a new subcutaneous treatment for hemophilia A patients with inhibitors. This update has been released following the first report of an anti-drug antibody to Emicizumab. MASAC’s update issues recommendations for providers and patients in case of […]

Genentech Releases Statement on Hemlibra Patient

The following is an excerpt from a statement from Genentech. Read the entire statement  HERE._________________________________________________________Genentech has recently learned that a patient in the Phase III HAVEN 2 clinical trial developed a neutralizing anti-drug antibody.For this patient, the anti-drug antibody resulted in reduced efficacy of HEMLIBRA.